微创手术与大范围或复杂肝切除术传统开腹术的比较效果
该回顾性队列研究纳入2014年NSQIP肝胆胰协作组65家医院的2819例肝切除术患者,比较微创手术与开腹手术的安全结局。调整混杂因素后,微创手术组严重并发症或死亡(SMM)及再手术或干预的比值显著低于开腹组,大范围肝切除亚组微创手术达到非劣效标准。
要点
- 微创肝切除与开腹相比,严重并发症或死亡及再手术或干预风险显著降低。
- 大范围肝切除亚组中微创手术的SMM比值无显著差异,但满足非劣效标准。
- 接受新辅助化疗的患者中,微创手术的SMM比值显著更低。
核心结论
- 微创大范围肝切除术的安全结局等同或优于传统开腹手术。
- 这些发现支持微创手术在大范围肝切除术中的当前应用。
研究设计与样本
- 回顾性队列研究,纳入2014年参与NSQIP肝胆胰协作组的65家医院中接受肝切除术的患者共2819例。
- 患者年龄58±14岁,女性占53%,25%接受微创手术。
主要发现
- 调整临床和手术因素后,微创手术组严重并发症或死亡(SMM)的比值显著低于开腹组(OR=0.57;95%CI 0.34-0.96;p=0.03)。
- 微创手术组再手术或干预的比值显著低于开腹组(OR=0.52;95%CI 0.29-0.93;p=0.03)。
- 大范围肝切除亚组(n=1015,13%为微创)中,微创手术的SMM比值无显著差异(OR=0.37;95%CI 0.13-1.11;p=0.08),但满足非劣效标准。
- 两组肝脏特异性并发症或再入院无差异。
- 接受新辅助化疗的患者中,微创手术的SMM比值显著更低(OR=0.33;95%CI 0.15-0.70;p=0.004)。
临床怎么用
- 对于大范围或复杂肝切除术,微创手术可作为安全的选择,其严重并发症或死亡及再手术或干预风险不高于开腹手术。
- 对于接受新辅助化疗的患者,微创手术可能进一步降低严重并发症或死亡风险。
- 微创手术的决策可能受外科医生经验等其他未评估因素影响,需个体化考虑。
局限性
- 回顾性研究设计。
- 微创手术的决策可能受未纳入评估的因素(如外科医生经验和其他患者因素)影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The benefits of minimally invasive surgery (MIS) for low-risk or minor liver resection are well established. There is growing interest in MIS for major hepatectomy (MH) and other challenging resections, but there remain unanswered questions of safety that prevent broad adoption of this technique. STUDY DESIGN: We conducted a retrospective cohort study of patients undergoing hepatectomy at 65 hospitals participating in the NSQIP Hepatopancreatobiliary Collaborative in 2014. We assessed serious morbidity or mortality (SMM; including organ/space infection and organ failure). Secondary outcomes included transfusion, bile leak, liver failure, reoperation or intervention, and 30-day readmission. We also measured factors considered to make resection more challenging (ie large tumors, cirrhosis, ≥3 concurrent resections, previous neoadjuvant chemotherapy, and morbid obesity). RESULTS: There were 2,819 patients who underwent hepatectomy (aged 58 ± 14 years; 53% female; 25% had MIS). After adjusting for clinical and operative factors, the odds of SMM (odds ratio [OR] = 0.57; 95% CI 0.34 to 0.96; p = 0.03) and reoperation or intervention (OR = 0.52; 95% CI 0.29 to 0.93; p = 0.03) were significantly lower for patients undergoing MIS compared with open. In the MH group (n = 1,015 [13% MIS]), there was no difference in the odds of SMM after MIS (OR = 0.37; 95% CI 0.13 to 1.11; p = 0.08); however, minimally invasive MH met criteria for noninferiority. There were no differences in liver-specific complications or readmission between the groups. Odds of SMM were significantly lower after MIS among patients who had received neoadjuvant chemotherapy (OR = 0.33; 95% CI 0.15 to 0.70; p = 0.004). CONCLUSIONS: In this large study of minimally invasive MH, we found safety outcomes that are equivalent or superior to conventional open surgery. Although the decision to offer MIS might be influenced by factors not included in this evaluation (eg surgeon experience and other patient factors), these findings support its current use in MH.
引用
- Thornblade LW, Shi X, Ruiz A, et al. Comparative Effectiveness of Minimally Invasive Surgery and Conventional Approaches for Major or Challenging Hepatectomy. J Am Coll Surg. 2017. PMID: 28163089. doi:10.1016/j.jamcollsurg.2017.01.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。